|  Help  |  About  |  Contact Us

Search our database by keyword

- or -

Examples

  • Search this entire website. Enter identifiers, names or keywords for genes, diseases, strains, ontology terms, etc. (e.g. Pax6, Parkinson, ataxia)
  • Use OR to search for either of two terms (e.g. OR mus) or quotation marks to search for phrases (e.g. "dna binding").
  • Boolean search syntax is supported: e.g. Balb* for partial matches or mus AND NOT embryo to exclude a term

Search results 501 to 600 out of 1170 for Erbb2

Category restricted to Publication (x)

<< First    < Previous  |  Next >    Last >>
0.041s

Categories

Category: Publication
« show all
Type Details Score
Publication
22271573 | J:181875
First Author: Schulz R
Year: 2012
Journal: J Exp Med
Title: Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.
Volume: 209
Issue: 2
Pages: 275-89
•
•
•
•
•
Publication
29487713 | J:294708
First Author: Yuan H
Year: 2018
Journal: Oncotarget
Title: MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment.
Volume: 9
Issue: 8
Pages: 8042-8053
•
•
•
•
•
Publication
36380187 | J:331598
First Author: Xu M
Year: 2022
Journal: Commun Biol
Title: Alteration in tyrosine phosphorylation of cardiac proteome and EGFR pathway contribute to hypertrophic cardiomyopathy.
Volume: 5
Issue: 1
Pages: 1251
•
•
•
•
•
Publication
15156151 | -
First Author: Marone R
Year: 2004
Journal: Nat Cell Biol
Title: Memo mediates ErbB2-driven cell motility.
Volume: 6
Issue: 6
Pages: 515-22
•
•
•
•
•
Publication
18955552 | -
First Author: Zaoui K
Year: 2008
Journal: J Cell Biol
Title: Memo-RhoA-mDia1 signaling controls microtubules, the actin network, and adhesion site formation in migrating cells.
Volume: 183
Issue: 3
Pages: 401-8
•
•
•
•
•
Publication
22412880 | -
First Author: Schlatter ID
Year: 2012
Journal: PLoS One
Title: MHO1, an evolutionarily conserved gene, is synthetic lethal with PLC1; Mho1p has a role in invasive growth.
Volume: 7
Issue: 3
Pages: e32501
•
•
•
•
•
Publication
22824790 | -
First Author: Sorokin AV
Year: 2013
Journal: Oncogene
Title: MEMO1, a new IRS1-interacting protein, induces epithelial-mesenchymal transition in mammary epithelial cells.
Volume: 32
Issue: 26
Pages: 3130-8
•
•
•
•
•
Publication
31597089 | J:284492
First Author: Hirukawa A
Year: 2019
Journal: Cell Rep
Title: Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy.
Volume: 29
Issue: 2
Pages: 249-257.e8
•
•
•
•
•
Publication
30463015 | J:270675
First Author: Wehde BL
Year: 2018
Journal: Cell Rep
Title: Janus Kinase 1 Plays a Critical Role in Mammary Cancer Progression.
Volume: 25
Issue: 8
Pages: 2192-2207.e5
•
•
•
•
•
Publication
11417997 | J:70644
First Author: Zelazny E
Year: 2001
Journal: Exp Mol Pathol
Title: Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Volume: 70
Issue: 3
Pages: 183-93
•
•
•
•
•
Publication
14991053 | J:121570
First Author: Bulavin DV
Year: 2004
Journal: Nat Genet
Title: Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.
Volume: 36
Issue: 4
Pages: 343-50
•
•
•
•
•
Publication
22665265 | J:189292
First Author: Lahlou H
Year: 2012
Journal: Cancer Res
Title: Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
Volume: 72
Issue: 12
Pages: 3080-90
•
•
•
•
•
Publication
21127199 | J:169326
First Author: Yang C
Year: 2011
Journal: Cancer Res
Title: The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers.
Volume: 71
Issue: 3
Pages: 937-45
•
•
•
•
•
Publication
27157621 | J:309306
First Author: Turpin J
Year: 2016
Journal: Oncogene
Title: The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.
Volume: 35
Issue: 47
Pages: 6053-6064
•
•
•
•
•
Publication
31222103 | J:278177
First Author: Gomez ML
Year: 2019
Journal: Oncogene
Title: SOD1 is essential for oncogene-driven mammary tumor formation but dispensable for normal development and proliferation.
Volume: 38
Issue: 29
Pages: 5751-5765
•
•
•
•
•
Publication
19638583 | J:151772
First Author: Sakamoto K
Year: 2009
Journal: Cancer Res
Title: Targeting janus kinase 2 in Her2/neu-expressing mammary cancer: Implications for cancer prevention and therapy.
Volume: 69
Issue: 16
Pages: 6642-50
•
•
•
•
•
Publication
23977064 | J:206347
First Author: Wallace JA
Year: 2013
Journal: PLoS One
Title: Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer.
Volume: 8
Issue: 8
Pages: e71533
•
•
•
•
•
Publication
15492286 | J:93643
First Author: Takeuchi N
Year: 2004
Journal: Cancer Res
Title: Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
Volume: 64
Issue: 20
Pages: 7588-95
•
•
•
•
•
Publication
27197158 | J:234852
First Author: Morrison Joly M
Year: 2016
Journal: Cancer Res
Title: Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
Volume: 76
Issue: 16
Pages: 4752-64
•
•
•
•
•
Publication
31862778 | J:285701
First Author: Citron F
Year: 2020
Journal: Cancer Res
Title: Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer.
Volume: 80
Issue: 5
Pages: 1064-1077
•
•
•
•
•
Publication
14634087 | J:132829
First Author: Piechocki MP
Year: 2003
Journal: J Immunol
Title: Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines.
Volume: 171
Issue: 11
Pages: 5787-94
•
•
•
•
•
Publication
26334628 | J:233887
First Author: Yong CS
Year: 2015
Journal: PLoS One
Title: Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene.
Volume: 10
Issue: 9
Pages: e0136817
•
•
•
•
•
Publication
19118005 | J:143031
First Author: Radkevich-Brown O
Year: 2009
Journal: Cancer Res
Title: Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice.
Volume: 69
Issue: 1
Pages: 212-8
•
•
•
•
•
Publication
20048073 | J:155732
First Author: Jacob JB
Year: 2010
Journal: Cancer Res
Title: Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity.
Volume: 70
Issue: 1
Pages: 119-28
•
•
•
•
•
Publication
38596303 | J:360588
First Author: Troise F
Year: 2024
Journal: Mol Ther Oncol
Title: Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors.
Volume: 32
Issue: 1
Pages: 200760
•
•
•
•
•
Publication
15073130 | J:90202
First Author: Finkle D
Year: 2004
Journal: Clin Cancer Res
Title: HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice.
Volume: 10
Issue: 7
Pages: 2499-511
•
•
•
•
•
Publication
31484792 | J:279261
 
First Author: Li J
Year: 2019
Journal: Sci Transl Med
Title: CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity.
Volume: 11
Issue: 508
•
•
•
•
•
Publication
37155852 | J:342348
First Author: Kim YS
Year: 2023
Journal: Proc Natl Acad Sci U S A
Title: An unanticipated discourse of HB-EGF with VANGL2 signaling during embryo implantation.
Volume: 120
Issue: 20
Pages: e2302937120
•
•
•
•
•
Publication
18700973 | J:142118
First Author: Young CD
Year: 2008
Journal: Breast Cancer Res
Title: Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3.
Volume: 10
Issue: 4
Pages: R70
•
•
•
•
•
Publication
38236941 | J:344324
First Author: Kuang X
Year: 2024
Journal: PLoS One
Title: USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity.
Volume: 19
Issue: 1
Pages: e0290837
•
•
•
•
•
Publication
16904607 | J:112688
First Author: Carraway KL 3rd
Year: 2006
Journal: Cancer Cell
Title: Co-opted integrin signaling in ErbB2-induced mammary tumor progression.
Volume: 10
Issue: 2
Pages: 93-5
•
•
•
•
•
Publication
9879008 | J:50160
First Author: Kuznetsov SB
Year: 1998
Journal: Genetika
Title: [Chromosome localization and analysis of synteny analysis of some genes in swine, cattle, and sheep (Artiodactyla)].
Volume: 34
Issue: 9
Pages: 1200-4
•
•
•
•
•
Publication
17446858 | J:120946
First Author: Ursini-Siegel J
Year: 2007
Journal: Nat Rev Cancer
Title: Insights from transgenic mouse models of ERBB2-induced breast cancer.
Volume: 7
Issue: 5
Pages: 389-97
•
•
•
•
•
Publication
17512406 | J:261822
First Author: Schug TT
Year: 2007
Journal: Cell
Title: Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors.
Volume: 129
Issue: 4
Pages: 723-33
•
•
•
•
•
Publication
15286714 | J:93776
First Author: Henry MD
Year: 2004
Journal: Oncogene
Title: Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice.
Volume: 23
Issue: 41
Pages: 6980-5
•
•
•
•
•
Publication
25544637 | J:218823
First Author: Costa C
Year: 2015
Journal: Cancer Cell
Title: Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer.
Volume: 27
Issue: 1
Pages: 97-108
•
•
•
•
•
Publication
17018635 | J:113384
First Author: Lu H
Year: 2006
Journal: Cancer Res
Title: The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens.
Volume: 66
Issue: 19
Pages: 9754-61
•
•
•
•
•
Publication
12368416 | J:79685
First Author: Jin Z
Year: 2002
Journal: J Nutr
Title: Soy isoflavones increase latency of spontaneous mammary tumors in mice.
Volume: 132
Issue: 10
Pages: 3186-90
•
•
•
•
•
Publication
24371223 | J:208167
First Author: Elangovan S
Year: 2014
Journal: Cancer Res
Title: The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival.
Volume: 74
Issue: 4
Pages: 1166-78
•
•
•
•
•
Publication
21518778 | J:173646
First Author: Hartman ZC
Year: 2011
Journal: Cancer Res
Title: HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.
Volume: 71
Issue: 13
Pages: 4380-91
•
•
•
•
•
Publication
36876343 | J:334749
First Author: Kryza D
Year: 2023
Journal: EMBO Mol Med
Title: From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumors.
Volume: 15
Issue: 4
Pages: e16732
•
•
•
•
•
Publication
15897883 | J:224965
First Author: Landis MD
Year: 2005
Journal: Oncogene
Title: Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
Volume: 24
Issue: 33
Pages: 5173-90
•
•
•
•
•
Publication
18381452 | J:133301
First Author: Worschech A
Year: 2008
Journal: Cancer Res
Title: Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.
Volume: 68
Issue: 7
Pages: 2436-46
•
•
•
•
•
Publication
37566035 | J:345443
 
First Author: Gómez-Vecino A
Year: 2023
Journal: Cells
Title: Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk.
Volume: 12
Issue: 15
•
•
•
•
•
Publication
26460950 | J:320216
First Author: Li YJ
Year: 2015
Journal: Oncotarget
Title: Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic mice.
Volume: 6
Issue: 35
Pages: 36943-54
•
•
•
•
•
Publication
14991069 | J:88661
First Author: Quaglino E
Year: 2004
Journal: J Clin Invest
Title: Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions.
Volume: 113
Issue: 5
Pages: 709-17
•
•
•
•
•
Publication
16186809 | J:112326
First Author: Muraoka-Cook RS
Year: 2006
Journal: Oncogene
Title: Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression.
Volume: 25
Issue: 24
Pages: 3408-23
•
•
•
•
•
Publication
18628471 | J:140420
First Author: Liby K
Year: 2008
Journal: Clin Cancer Res
Title: Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.
Volume: 14
Issue: 14
Pages: 4556-63
•
•
•
•
•
Publication
25972601 | J:222936
 
First Author: Zacarias-Fluck MF
Year: 2015
Journal: J Natl Cancer Inst
Title: Effect of cellular senescence on the growth of HER2-positive breast cancers.
Volume: 107
Issue: 5
•
•
•
•
•
Publication
15793299 | J:97061
First Author: Astolfi A
Year: 2005
Journal: Am J Pathol
Title: Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.
Volume: 166
Issue: 4
Pages: 1205-16
•
•
•
•
•
Publication
14502219 | J:86083
First Author: Sacco MG
Year: 2003
Journal: Gene Ther
Title: Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer.
Volume: 10
Issue: 22
Pages: 1903-9
•
•
•
•
•
Publication
16224592 | J:104186
First Author: Anisimov VN
Year: 2005
Journal: Bull Exp Biol Med
Title: Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice.
Volume: 139
Issue: 6
Pages: 721-3
•
•
•
•
•
Publication
12602922 | J:81932
First Author: Kurt RA
Year: 2003
Journal: Breast Cancer Res Treat
Title: Altered chemokine receptor sensitivity in FVBN202 rat neu transgenic mice.
Volume: 77
Issue: 3
Pages: 225-32
•
•
•
•
•
Publication
26554829 | J:230586
First Author: Josefsson A
Year: 2016
Journal: Cancer Res
Title: Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer.
Volume: 76
Issue: 2
Pages: 472-9
•
•
•
•
•
Publication
24875800 | J:254110
 
First Author: Rich BS
Year: 2014
Journal: Sci Rep
Title: Endogenous antibodies for tumor detection.
Volume: 4
Pages: 5088
•
•
•
•
•
Publication
21908736 | J:179318
First Author: Rowswell-Turner RB
Year: 2011
Journal: J Immunol
Title: Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation.
Volume: 187
Issue: 8
Pages: 4109-18
•
•
•
•
•
Publication
12070308 | J:77155
First Author: Yang YA
Year: 2002
Journal: J Clin Invest
Title: Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.
Volume: 109
Issue: 12
Pages: 1607-15
•
•
•
•
•
Publication
16785502 | J:114945
First Author: Knutson KL
Year: 2006
Journal: J Immunol
Title: IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.
Volume: 177
Issue: 1
Pages: 84-91
•
•
•
•
•
Publication
10667575 | J:60217
First Author: Ménard S
Year: 2000
Journal: Cancer Res
Title: Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model.
Volume: 60
Issue: 2
Pages: 273-5
•
•
•
•
•
Publication
12750262 | J:83495
First Author: Yang X
Year: 2003
Journal: Cancer Res
Title: Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice.
Volume: 63
Issue: 10
Pages: 2425-33
•
•
•
•
•
Publication
15883172 | J:101130
First Author: Ercolini AM
Year: 2005
Journal: J Exp Med
Title: Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.
Volume: 201
Issue: 10
Pages: 1591-602
•
•
•
•
•
Publication
16125352 | J:102134
First Author: Anisimov VN
Year: 2005
Journal: Exp Gerontol
Title: Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
Volume: 40
Issue: 8-9
Pages: 685-93
•
•
•
•
•
Publication
18922913 | J:140553
First Author: Park KH
Year: 2008
Journal: Cancer Res
Title: Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.
Volume: 68
Issue: 20
Pages: 8400-9
•
•
•
•
•
Publication
34298925 | J:308911
 
First Author: Khan AUH
Year: 2021
Journal: Int J Mol Sci
Title: Effects of Chronic Low-Dose Internal Radiation on Immune-Stimulatory Responses in Mice.
Volume: 22
Issue: 14
•
•
•
•
•
Publication
18922910 | J:140554
First Author: Davis VL
Year: 2008
Journal: Cancer Res
Title: Black cohosh increases metastatic mammary cancer in transgenic mice expressing c-erbB2.
Volume: 68
Issue: 20
Pages: 8377-83
•
•
•
•
•
Publication
26729790 | J:231167
First Author: Jiang Y
Year: 2016
Journal: Cancer Res
Title: A Sucrose-Enriched Diet Promotes Tumorigenesis in Mammary Gland in Part through the 12-Lipoxygenase Pathway.
Volume: 76
Issue: 1
Pages: 24-9
•
•
•
•
•
Publication
15711557 | J:97114
First Author: Muller AJ
Year: 2005
Journal: Nat Med
Title: Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.
Volume: 11
Issue: 3
Pages: 312-9
•
•
•
•
•
Publication
20881963 | J:166077
First Author: Gonzalez-Suarez E
Year: 2010
Journal: Nature
Title: RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
Volume: 468
Issue: 7320
Pages: 103-7
•
•
•
•
•
Publication
9635596 | J:48749
First Author: Rowse GJ
Year: 1998
Journal: Cancer Res
Title: Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis.
Volume: 58
Issue: 12
Pages: 2675-9
•
•
•
•
•
Publication
17020999 | J:117015
First Author: Liby K
Year: 2006
Journal: Clin Cancer Res
Title: The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.
Volume: 12
Issue: 19
Pages: 5902-9
•
•
•
•
•
Publication
19287973 | J:158932
First Author: Tomblyn S
Year: 2009
Journal: Int J Oncol
Title: Combination therapy using three novel prolactin receptor antagonist-based fusion proteins effectively inhibits tumor recurrence and metastasis in HER2/neu transgenic mice.
Volume: 34
Issue: 4
Pages: 1139-46
•
•
•
•
•
Publication
20308630 | J:160487
First Author: Lu H
Year: 2010
Journal: J Immunol
Title: Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade.
Volume: 184
Issue: 9
Pages: 5360-7
•
•
•
•
•
Publication
28373182 | J:242302
First Author: Rossi EL
Year: 2017
Journal: Cancer Res
Title: Energy Balance Modulation Impacts Epigenetic Reprogramming, ERα and ERβ Expression, and Mammary Tumor Development in MMTV-neu Transgenic Mice.
Volume: 77
Issue: 9
Pages: 2500-2511
•
•
•
•
•
Publication
17114432 | J:120600
First Author: Rolla S
Year: 2006
Journal: J Immunol
Title: Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice.
Volume: 177
Issue: 11
Pages: 7626-33
•
•
•
•
•
Publication
27058424 | J:263350
First Author: Casado-Medrano V
Year: 2016
Journal: Oncotarget
Title: A new role of the Rac-GAP β2-chimaerin in cell adhesion reveals opposite functions in breast cancer initiation and tumor progression.
Volume: 7
Issue: 19
Pages: 28301-19
•
•
•
•
•
Publication
21937679 | J:177356
First Author: Mamessier E
Year: 2011
Journal: Cancer Res
Title: Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.
Volume: 71
Issue: 21
Pages: 6621-32
•
•
•
•
•
Publication
22460789 | J:183531
First Author: Liu JC
Year: 2012
Journal: Proc Natl Acad Sci U S A
Title: Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.
Volume: 109
Issue: 15
Pages: 5832-7
•
•
•
•
•
Publication
24487029 | J:208323
First Author: Deng T
Year: 2014
Journal: Cancer Res
Title: shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer.
Volume: 74
Issue: 7
Pages: 2119-30
•
•
•
•
•
Publication
17699716 | J:138101
First Author: Mosley JD
Year: 2007
Journal: Mol Cancer Ther
Title: Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer.
Volume: 6
Issue: 8
Pages: 2188-97
•
•
•
•
•
Publication
8895508 | J:53489
First Author: Davies MP
Year: 1996
Journal: Oncogene
Title: Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours.
Volume: 13
Issue: 8
Pages: 1631-7
•
•
•
•
•
Publication
24516139 | J:206821
First Author: Gonzalez ME
Year: 2014
Journal: Proc Natl Acad Sci U S A
Title: EZH2 expands breast stem cells through activation of NOTCH1 signaling.
Volume: 111
Issue: 8
Pages: 3098-103
•
•
•
•
•
Publication
12902523 | J:85703
First Author: Wolpoe ME
Year: 2003
Journal: J Immunol
Title: HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.
Volume: 171
Issue: 4
Pages: 2161-9
•
•
•
•
•
Publication
21078982 | J:167163
First Author: Guo HB
Year: 2010
Journal: Proc Natl Acad Sci U S A
Title: Specific posttranslational modification regulates early events in mammary carcinoma formation.
Volume: 107
Issue: 49
Pages: 21116-21
•
•
•
•
•
Publication
21996747 | J:186131
First Author: Lo PK
Year: 2012
Journal: Oncogene
Title: CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Volume: 31
Issue: 21
Pages: 2614-26
•
•
•
•
•
Publication
16751376 | J:115031
First Author: Nair RE
Year: 2006
Journal: J Immunol
Title: Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
Volume: 176
Issue: 12
Pages: 7325-34
•
•
•
•
•
Publication
17304628 | J:118653
First Author: Kmieciak M
Year: 2007
Journal: Eur J Immunol
Title: HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.
Volume: 37
Issue: 3
Pages: 675-85
•
•
•
•
•
Publication
10910070 | J:63566
First Author: Reilly RT
Year: 2000
Journal: Cancer Res
Title: HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
Volume: 60
Issue: 13
Pages: 3569-76
•
•
•
•
•
Publication
16849459 | J:137978
First Author: Knutson KL
Year: 2006
Journal: J Immunol
Title: Immunoediting of cancers may lead to epithelial to mesenchymal transition.
Volume: 177
Issue: 3
Pages: 1526-33
•
•
•
•
•
Publication
15253274 | J:91417
First Author: Kosanke S
Year: 2004
Journal: Comp Med
Title: Mammary tumor heterogeneity in wt-ErbB-2 transgenic mice.
Volume: 54
Issue: 3
Pages: 280-7
•
•
•
•
•
Publication
21932419 | J:186138
First Author: Margalit O
Year: 2012
Journal: Int J Cancer
Title: Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function.
Volume: 131
Issue: 4
Pages: E562-8
•
•
•
•
•
Publication
19017793 | J:142214
First Author: Xue Y
Year: 2008
Journal: Proc Natl Acad Sci U S A
Title: Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome.
Volume: 105
Issue: 47
Pages: 18513-8
•
•
•
•
•
Publication
19276366 | J:147366
First Author: Santisteban M
Year: 2009
Journal: Cancer Res
Title: Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells.
Volume: 69
Issue: 7
Pages: 2887-95
•
•
•
•
•
Publication
20841468 | J:164678
First Author: Cheng X
Year: 2010
Journal: Cancer Res
Title: Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis.
Volume: 70
Issue: 19
Pages: 7684-9
•
•
•
•
•
Publication
23430951 | J:198306
First Author: Pierpaoli E
Year: 2013
Journal: Carcinogenesis
Title: Effect of annatto-tocotrienols supplementation on the development of mammary tumors in HER-2/neu transgenic mice.
Volume: 34
Issue: 6
Pages: 1352-60
•
•
•
•
•
Publication
18421311 | J:153418
First Author: Sas S
Year: 2008
Journal: Cancer Gene Ther
Title: Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
Volume: 15
Issue: 10
Pages: 655-66
•
•
•
•
•
Publication
31355130 | J:281857
 
First Author: Dodda BR
Year: 2019
Journal: Front Oncol
Title: Co-administering Melatonin With an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-Positive Breast Cancer.
Volume: 9
Pages: 525
•
•
•
•
•
Publication
22038845 | J:186122
First Author: Dong LF
Year: 2012
Journal: Int J Cancer
Title: α-Tocopheryloxyacetic acid is superior to α-tocopheryl succinate in suppressing HER2-high breast carcinomas due to its higher stability.
Volume: 131
Issue: 5
Pages: 1052-8
•
•
•
•
•
Publication
19148488 | J:156981
First Author: Jacquemart IC
Year: 2009
Journal: Int J Oncol
Title: Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.
Volume: 34
Issue: 2
Pages: 517-28
•
•
•
•
•
Publication
17970045 | J:133602
First Author: Freitas I
Year: 2007
Journal: Anticancer Res
Title: Iron accumulation in mammary tumor suggests a tug of war between tumor and host for the microelement.
Volume: 27
Issue: 5A
Pages: 3059-65
•
•
•
•
•
Publication
23269276 | J:194361
First Author: Ladd JJ
Year: 2013
Journal: Cancer Res
Title: Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women.
Volume: 73
Issue: 5
Pages: 1502-13
•
•
•
•
•




MouseMine is a collaboration between MGI at The Jackson Laboratory and the InterMine project at the Cambridge Systems Biology Centre. MouseMine is funded through a grant from the NIH/NHGRI.The Jackson Laboratory makes no representation about the suitability or accuracy of this software or data for any purpose, and makes no warranties, either express or implied, including merchantability and fitness for a particular purpose or that the use of this software or data will not infringe any third party patents, copyrights, trademarks, or other rights. the software and data are provided "as is". This software and data are provided to enhance knowledge and encourage progress in the scientific community and are to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of the Jackson Laboratory.

Copyright © 2017 by The Jackson Laboratory. All Rights Reserved

© 2002 - 2017 Department of Genetics, University of Cambridge, Downing Street,
Cambridge CB2 3EH, United Kingdom